--- title: "ASX Penny Stock Highlights: Australian Clinical Labs Among 3 Noteworthy Picks" type: "News" locale: "en" url: "https://longbridge.com/en/news/290133985.md" description: "Amidst cautious market sentiment following the US Fed's rate decision, Simply Wall St highlights three ASX penny stocks: Australian Clinical Labs (ACL), Barton Gold Holdings (BGD), and Tyro Payments (TYR). ACL offers pathology services with attractive valuation despite earnings declines. BGD is a debt-free, pre-revenue gold explorer with reduced losses. TYR provides payment solutions, remaining debt-free but facing negative earnings growth trends." datetime: "2026-06-18T03:09:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/290133985.md) - [en](https://longbridge.com/en/news/290133985.md) - [zh-HK](https://longbridge.com/zh-HK/news/290133985.md) --- # ASX Penny Stock Highlights: Australian Clinical Labs Among 3 Noteworthy Picks As Australian shares brace for a dip following the U.S. Federal Reserve's decision to hold interest rates steady, market participants are keenly observing how this will impact local equities. Despite the cautious sentiment, opportunities still abound for investors willing to explore beyond the major indices. Penny stocks, though often seen as a nod to earlier trading eras, continue to offer intriguing potential; these smaller or newer companies can present significant growth prospects when backed by solid financials and strong fundamentals. Underneath we present a selection of stocks filtered out by our screen. ## Australian Clinical Labs (ASX:ACL) **Simply Wall St Financial Health Rating:** ★★★★☆☆ **Overview:** Australian Clinical Labs Limited offers pathology diagnostic services in Australia and has a market cap of A$419.28 million. **Operations:** The company's revenue is primarily derived from its Pathology/Clinical Laboratory Services segment, which generated A$737.89 million. **Market Cap:** A$419.28M Australian Clinical Labs faces challenges with negative earnings growth over the past year and a declining profit trend of 33.8% annually over five years. Despite this, it trades at an attractive valuation, 89.3% below its estimated fair value, and has reduced its debt-to-equity ratio significantly from 219.3% to 47.8%. The company’s interest payments are well covered by EBIT at a ratio of 4.9x, though short-term assets do not cover liabilities adequately. With a seasoned management team averaging seven years in tenure, ACL is poised for potential improvements under new CEO Greg Horan’s leadership starting August 2026. - Dive into the specifics of Australian Clinical Labs here with our thorough balance sheet health report. - Evaluate Australian Clinical Labs' prospects by accessing our earnings growth report. ASX:ACL Debt to Equity History and Analysis as at Jun 2026 ## Barton Gold Holdings (ASX:BGD) **Simply Wall St Financial Health Rating:** ★★★★★★ **Overview:** Barton Gold Holdings Limited, with a market cap of A$203.74 million, is involved in the exploration and development of mineral properties in Australia. **Operations:** Barton Gold Holdings Limited has not reported any revenue segments. **Market Cap:** A$203.74M Barton Gold Holdings Limited, with a market cap of A$203.74 million, is pre-revenue and currently unprofitable but has managed to reduce its losses over the past five years. The company is debt-free, with short-term assets (A$18.6M) exceeding both short and long-term liabilities. Barton recently completed a follow-on equity offering raising A$25.9 million, which may support its cash runway of over a year if free cash flow continues to decline at historical rates. The management team and board are considered experienced, potentially aiding in navigating challenges as Barton focuses on developing precious metal projects in South Australia’s Gawler Craton region. - Navigate through the intricacies of Barton Gold Holdings with our comprehensive balance sheet health report here. - Explore Barton Gold Holdings' analyst forecasts in our growth report. ASX:BGD Financial Position Analysis as at Jun 2026 ## Tyro Payments (ASX:TYR) **Simply Wall St Financial Health Rating:** ★★★★★★ **Overview:** Tyro Payments Limited offers integrated payment solutions and value-added services in Australia, with a market cap of A$446.64 million. **Operations:** The company's revenue is primarily derived from its Payments segment, which generated A$463.77 million, followed by its Banking segment with A$15.35 million. **Market Cap:** A$446.64M Tyro Payments Limited, with a market cap of A$446.64 million, derives substantial revenue from its Payments segment (A$463.77 million) and remains debt-free. Despite high-quality earnings and surpassing liabilities with assets (short-term: A$214.4M; long-term: A$64.7M), Tyro's recent negative earnings growth (-18.2%) contrasts its 5-year profitability trend, and future earnings are expected to decline by 2% annually over three years. The management team is relatively new with an average tenure of 1.8 years, while the board is seasoned at 4.8 years average tenure, potentially impacting strategic direction amidst industry challenges like merchant card payment cost reviews by the Reserve Bank of Australia. - Get an in-depth perspective on Tyro Payments' performance by reading our balance sheet health report here. - Review our growth performance report to gain insights into Tyro Payments' future. ASX:TYR Financial Position Analysis as at Jun 2026 ## Make It Happen - Discover the full array of 392 ASX Penny Stocks right here. - Curious About Other Options? Outshine the giants: these 14 early-stage AI stocks could fund your retirement. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [ACL.AU](https://longbridge.com/en/quote/ACL.AU.md) - [BGD.AU](https://longbridge.com/en/quote/BGD.AU.md) - [TYR.AU](https://longbridge.com/en/quote/TYR.AU.md) ## Related News & Research - [ACL: Strong FY26 margin and cash flow, with stable outlook and continued shareholder returns](https://longbridge.com/en/news/296033240.md) - [Infrastructure Sterilisation Drilling Begins at Tunkillia | BGDFF Stock News](https://longbridge.com/en/news/296414493.md) - [Iris Metals Seeks ASX Quotation for Incentive Scheme Shares](https://longbridge.com/en/news/295871864.md) - [Optomed Oyj (HEL:OPTOMED) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year](https://longbridge.com/en/news/296297835.md) - [GuideAI Health shares begin trading on Frankfurt Stock Exchange under ZN0](https://longbridge.com/en/news/295976320.md)